Postmenopausal women taking anastrozole as a chemopreventive treatment do not have impaired cognitive performance
Friday, September 5, 2008 - 10:56
in Health & Medicine
New results of a sub-study carried out as part of a worldwide breast cancer prevention study (IBIS-II) show that after two years of taking the aromatase inhibitor, anastrozole, postmenopausal women at high risk of breast cancer do not have impaired cognitive performance.